Acute Lymphoblastic Leukemia (ALL | sciencenewsnet.in

Breaking News

Future Parents More Likely to Get RSV Vaccine When Pregnant if Aware That RSV Can Be a Serious Illness in Infants

Transforming Agriculture and Medicine: The Impact of Gene-Based Breeding (GBB)

Advancing CBSD Resistance in Cassava: A Comprehensive Review of Breeding Strategies and the Role of New Plant Technologies

ADDMAN Secures Qualification Project for CuNi Submarine Fittings with the US Navy

It’s easier now to treat opioid addiction with medication — but use has changed little

Researchers Publish Final Results of Key Clinical Trial for Gene Therapy for Sickle Cell Disease

A new report from the American Lung Association shows nearly 40% of people across the U.S. are living in areas that are heavily polluted.

Five facilities at Argonne where climate solutions are front and center

For Immigrants to Canada, Risk of MS Increases with Proportion of Life Spent There

Use of Acid Reflux Drugs Linked to Higher Risk of Migraine

25 Apr, 2024

To wipe childhood cancer off the map, scientists must chart its genomic landscape

September 1, 2022 sarah JonasResearch Results

Scientists at St. Jude sequenced more samples of the most common childhood cancer than ever before to fully characterize the potential mutations driving disease.

Partnership with China prompts change in care for high-risk type of leukemia

January 16, 2020 sarah JonasResearch Results

Researchers from St. Jude Children’s Research Hospital and the Chinese Children’s Cancer Group led the first randomized, Phase III clinical trial comparing targeted therapies for acute lymphoblastic leukemia (ALL) driven by the Philadelphia chromosome. Results showed that the drug dasatinib provides more benefit than the standard of care, which led to changes in the way this leukemia is treated. The findings were reported today in JAMA Oncology.